Morgan Stanley & Co. International plc is acting as the only real book-running supervisor for the offering and Aegis Capital Corp. Is acting as a co-manager.. China Biologic prices follow-on offering of common stock in $38.00 per share China Biologic Products, Inc. , a leading plasma-based biopharmaceutical business in China, today announced the pricing of a follow-on giving of 1 1,550,000 shares of common stock at a public supplying price of $38.00 per share. THE BUSINESS will be offering 800, 000 shares and a selling stockholder will be providing 750,000 shares of common stock.They discovered no difference in mortality or major problems between your two groups; however, major problems occurred more often in individuals who received several units of red bloodstream cells. Gastrointestinal problems, renal failure needing dialysis, and respiratory failing were also more prevalent among patients receiving several units of red bloodstream cells. The Culture of Thoracic Surgeons and the Culture of Cardiovascular Anesthesiologists have released scientific practice guidelines on bloodstream conservation; nevertheless the guidelines have already been applied generally to coronary artery bypass grafting surgery.